Stock Market News
Motif Bio pushes back FDA submission for iclaprim
Clinical-stage biopharmaceutical company Motif Bio updated the market on the status and timeline for submission of its new drug application (NDA) to the US Food and Drug Administration (FDA) on Tuesday, for its targeted gram-positive investigational antibiotic, iclaprim.
The AIM-traded firm said iclaprim was for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
It said that, in consultation with its advisers, it had decided that in order to ensure a complete and high-quality submission, it would be prudent to take additional time.
As a result, Motif Bio now expected that the NDA would be submitted to the FDA during the second quarter of 2018.
"There are many components that go into an NDA submission and our aggressive timeline was contingent upon all outstanding items being completed to provide sufficient time to quality check and then publish the document," said Motif Bio CEO Graham Lumsden.
"Most components are complete, but given the importance of the submission, we made the decision that it was in the best interests of the company and all stakeholders to allow more time to ensure we submit the strongest possible application."
The AIM-traded firm said iclaprim was for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
It said that, in consultation with its advisers, it had decided that in order to ensure a complete and high-quality submission, it would be prudent to take additional time.
As a result, Motif Bio now expected that the NDA would be submitted to the FDA during the second quarter of 2018.
"There are many components that go into an NDA submission and our aggressive timeline was contingent upon all outstanding items being completed to provide sufficient time to quality check and then publish the document," said Motif Bio CEO Graham Lumsden.
"Most components are complete, but given the importance of the submission, we made the decision that it was in the best interests of the company and all stakeholders to allow more time to ensure we submit the strongest possible application."
Related share prices |
---|
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price